Drug distribution in obesity and following bariatric surgery: A literature review

Obesity Surgery

Volumn 6, Issue 1, 1996, Pages 17-27

  Macgregor, Alex M C ^a   Boggs, Lisa ^b  

^a N Florida Regional Medical Center ^*  (United States)

^b UNIVERSITY OF FLORIDA   (United States)

Author keywords

Absorption; Bariatric surgery; Distribution; Drugs; Gastric bypass; Gastroplasty; Jejuno ileal bypass; Morbid obesity; Obesity; Post operative

Indexed keywords

AMINOSALICYLIC ACID; AMPICILLIN; CEFALEXIN; CLORAZEPATE; DIAZEPAM; DIGOXIN; ETHAMBUTOL; ETHIONAMIDE; NITROFURANTOIN; PHENAZONE; PROPRANOLOL; QUINIDINE; RANITIDINE; SULFADIMIDINE; SULFAFURAZOLE; SULFAMETHOXAZOLE; TETRACYCLINE; THEOPHYLLINE;

ADIPOSE TISSUE; BODY SIZE; BODY SURFACE; BODY WEIGHT; CORRELATION FUNCTION; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; GASTROPLASTY; HUMAN; INTESTINE ABSORPTION; LEAN BODY WEIGHT; MEDICAL LITERATURE; OBESITY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW; SMALL INTESTINE; STOMACH BYPASS; STOMACH EMPTYING;

EID: 0030067066     PISSN: 09608923     EISSN: None     Source Type: Journal    
DOI: 10.1381/096089296765557222     Document Type: Review

References (88)

1. Abernethy DR, Greenblatt DJ. Drug disposition in obese humans: an update. Clin Pharmacokinet. 1986; 11:199-213.
2. Travell J. The influence of the hydrogen ion concentration on the absorption of alkaloids from the stomach. J Pharmacol Exp Ther 1940; 69:21-33.
3. Shanker LS, Shore PA, Brodie BB, et al. Absorption of drugs from the stomach: I. The rat. J Pharmacol Exp Ther 1957; 120:528-39.
4. Hogben CAM, Tocco DJ, Brodie BB, et al. On the mechanism of intestinal absorption of drugs. J Pharmacol Exp Ther 1959; 125:275-82.
5. Levine RR. Facilitation and inhibition of drug absorption. in: Rummel W, ed. International Encyclopedia of Pharmacology and Therapeutics. London: Pergammon Press 1970: section 39B.
6. Binns TB. The absorption of drugs from the alimentary tract, lungs and skin. Br J Hosp Med 1971; 6:133-42.
7. Siurala M, Mustala O, Jussila J. Absorption of acetyl salicylic acid by a normal and an atrophic gastric mucosa. Scand J Gastroenterol 1969; 4:269-73.
8. Magnussen MP. The effect of ethanol on the gastrointestinal absorption of drugs in the rat. Acta Pharmacol et Toxicol 1968; 26:130-44.
9. Heading RC, Nimmo J, Prescott LF, et al. The dependence of paracetamol absorption on the rate of gastric emptying. Br J Pharmacol 1973; 47:415-22.
10. Pottage A, Nimmo J, Prescott LF, et al. The absorption of aspirin and paracetamol in patients with achlorhydria. J Pharm Pharmacol 1974; 26:144-5.
11. Schedl WP, Wilson HD. Permeability of the rat intestine to sodium, chloride and water. Gastroenterol 1968; 54:1267.
12. Wilson JP. Surface area of the small intestine in man. Gut 1967; 8:618-21.
13. Booth CC. Sites of absorption in the small intestine. Fed Proc 1967; 26:1583-8.
14. 12 absorption and the intestinal cell surface. Fed Proc 1969; 28:41-5.
15. Marcus CS, Lengemann FW. Use of radioyttrium to study food movement in the small intestine of the rat. J Nutr 1962; 76:179-82.
16. 85 from solid and liquid food at various levels of the alimentary tract of the rat. J Nutr 1962; 77:155-60.
17. Lengemann FW, Comar CL. Distribution of absorbed strontium-85 and calcium-45 as influenced by lactose. Amer J Physiol 1961; 200:1051-4.
18. Lode H, Frish D, Naumann P. Oral antibiotic therapy in patients with partial gastrectomy. In: Duke S, ed. Progress in chemotherapy. Hellenic Society of Chemotherapy. 8th Int'l Congress of Chemotherapy, Athens. 1974; 1:543-7.
19. Ochs HR, Greenblatt DJ, Allen MD, et al., Effect of age and Billroth gastrectomy on absorption of desmethyldiazepam from clorazepate. Clin Pharmacol Therapeut 1979; 26:449-56.
20. Ochs HR, Otten H, Greenblatt DJ, et al. Diazepam absorption. Effects of age, sex and Billroth gastrectomy. Digest Dis Sci 1982; 27:225-30.
21. Beermann B, Hellstrom K, Rosen A. The gastrointestinal absorption of digoxin in seven patients with gastric or small intestinal reconstructions. Acta Med Scand 1973; 193:293-7.
22. Ochs, HR, Bodem G, Kodrat G, et al. Biologische Verfugbarkeit von Digoxin bei Patienten mit und ohn Magenresektion nach Billroth II. Deutsch Med Wochenschr 1975; 100:2430-4.
23. Venho VMK, Aukee S, Jussila J, et al. Effect of gastric surgery on gastrointestinal drug absorption in man. Scand J Gastroenterol 1975; 10:43-7.
24. Matilla MJ, Friman A, Lami TKI, et al. Absorption of ethionamide, isoniazid and aminosalicylic acid from the post-resection gastrointestinal tract. Ann Med Exper Biol Fenn 1969; 47:209-12.
25. Schmid E, Schaudig H, Meythaler C, et al. Zur Resoption von Nitrofurantoin bei Magenresezierten. Z Gastroenterol 1966; 4:276-8.
26. Schaefer HG, Harrison D, Hocking MP, et al. Effects of truncal vagotomy and partial gastrectomy on the pharmacokinetics of Propranolol enantiomers in dogs. J Pharmaceut Sci 1990; 79:292-4.
27. Andreasen PB, Dano P, Kirk H, et al. Drug absorption and hepatic drug metabolism in patients with different types of intestinal shunt operation for obesity. A study with phenazone. Scand J Gastroenterol 1977; 12:531-5.
28. Makil O, Kaltenbach ML, Limberg J. et al. Pharmacokinetics of Ranitidine after partial gastrectomy in dogs. J Pharmaceut Sci 1991; 80:1034-6.
29. Adami GF, Gandolfo P, Esposito M, et al. Orally administered serum ranitidine concentration after biliopancreatic diversion for obesity. Obes Surg 1991; 1:293-4.
30. Calvo R, Sarabia S, Carlos R, et al. Sulfamethazine absorption and disposition: effect of surgical procedures for gastroduodenal ulcers. Biopharm Drug Dispos 1987; 8:115-24.
31. Antonioli JA, Scheling JL, Steininger E, et al. Effect of gastrectomy and of an anticholinergic drug on the gastrointestinal absorption of a sulphonamide in man. Int J Clin Pharmacol 1971; 5:212-15.
32. Garrett ER, Suverkrup RS, Eberst K, et al. Surgically affected sulfisoxazole pharmacokinetics in the morbidly obese. Biopharm Drug Dispos 1981; 2:329-65.
33. Ochs HR, Greenblatt DJ, Dengler HJ. Absorption of oral tetracycline in patients with Billroth II gastrectomy. J Pharmacokinetik Biopharm 1978; 6:295-303.
34. Limberg J, Harrison D, Hocking M, et al. Theophylline absorption and gastric emptying after partial gastrectomy in dogs. J Pharmaceut Sci 1990; 79:968-9.
35. Owyang C, Louie DS, Tatum D. Feedback regulation of pancreatic enzyme secretion. Suppression of cholecystokinin release by trypsin. J Clin Invest 1986; 77:2042-7.
36. Toskes PP. Therapy of pancreatic disease. In: Wolfe MM, ed. Gastrointestinal pharmacotherapy. Philadelphia: WB Saunders, Co. 1983:265-75.
37. Graham DY, Sackman JW. Mechanism of increase in steatorrhea with calcium and magnesium in exocrine pancreatic insufficiency. An animal model. Gastroenterology 1982; 83:638-44.
38. Benet LZ, Massoud N. Pharmacokinetics. In: Benet LZ, Massoud N, Gambertoglio JG, eds. Pharmacokinetic basis for drug treatment. New York: Raven Press. 1984:1-29.
39. Alexander JK. Obesity and cardiac performance. Am J Cardiol 1964; 14:860-5.
40. deDivitis O, Fazio S, Pettito M, et al. Obesity and cardiac function. Circulation 1981; 64:477-82.
41. Kjellberg J, Reisenstein P. Body composition in obesity. Acta Med Scand 1970; 188:161-9.
42. Naeye RL, Roode P. The sizes and numbers of cells in visceral organs in human obesity. Am J Clin Path. 1970; 54:251-3.
43. Blouin RA, Chandler MHH. Special pharmacokinetic considerations in the obese. In: Evans WE, Schentag JJ, Jusko WJ, eds. Applied Pharmacokinetics: Principles of Therapeutic Drug Monitoring. Vancouver, WA: Applied Therapeutics, Inc. 1992: chapter 11.
44. Blouin RA, Kolpek JH, Mann HJ. Influence of obesity on drug disposition. Clin Pharmacokinet 1987; 6:706-14.
45. Cheymol G. Clinical pharmacokinetics of drugs in obesity. Clin Pharmacokinet 1993; 25:103-14.
46. Reuning RH, Geraets DR, Rocci ML, et al. Digoxin. In: Evans WE, Schentag JJ, Jusko WJ. eds. Applied Pharmacokinetics: Principles of Therapeutic Drug Monitoring. Vancouver, WA: Applied Therpeutics, Inc. 1992: chapter 20.
47. Tozer TN, Winter ME. Phenytoin. In: Evans WE, Schentag JJ, Jusko WJ. eds. Applied Pharmacokinetics: Principles of Drug Monitoring. Vancouver, WA: Applied Therapeutics Inc. 1992: chapter 25.
48. MacKichan JJ. Influence of protein binding and use of unbound (free) drug concentrations. In: Evans WE, Schentag JJ, Jusko WJ, eds. Applied Pharmacokinetics: Principles of Therapeutic Drug Monitoring. Vancouver, WA. Applied Therapeutics Inc. 1992: chapter 5.
49. 1-acid glycoprotein and the binding of drugs in obesity. Br J Clin Pharmacol. 1983; 16:751-4.
50. 1-acid glycoprotein in moderately obese male subjects. Br J Clin Pharmacol 1984; 18:941-6.
51. Andersen T, Gluud C. Liver morphology in morbid obesity: a literature study. Int J Obesity. 1984; 8:97-106.
52. Andersen T, Christoffersen P, Gluud C. The liver in consecutive patients with morbid obesity. A clinical, morphological, and biochemical study. Int J Obesity 1984; 8:107-15.
53. Mulder GJ, Weitering JG, Scholtens E, et al. Extrahepatic sulfation and glucuronidation in the rat in vivo: determination of the hepatic extraction ratio of harmol and the extrahepatic contribution to harmol conjugation. Biochem Pharmacol 1984; 33:3081-7.
54. Milsap RL, Plaisance KI, Jusko WJ. Prednisone disposition in obese men. Clin Pharmacol Ther. 1984; 36:824-31.
55. Abernethy DR, Greenblatt DJ, Divoli M, et al. The influence of obesity on the pharmacokinetics of oral alprazolam and triazolam. Clin Pharmacokinet 1984; 9:177-83.
56. Caraco Y, Zylber-Katz E, Berry EM, et al. Significant weight reduction in obese subjects enhances carbemazepine elimination. Clin Pharmacol Ther 1992; 51:501-6.
57. 7. Matzke GR, Millikin SP. Influence of renal function and dialysis on drug disposition. In: Evans WE, Schentag JJ, Jusko WJ, eds. Applied Pharmacokinetics: Principles of Therapeutic Drug Monitoring. Vancouver WA. Applied Therapeutics, Inc. 1992: chapter 8.
58. Stockholm KH, Biochner-Mortensen J, Hoilund-Carlsen PF. Increased glomerular filtration rate and adrenocortical function in obese women. Int J Obes 1980; 4:57-63.
59. Dionne RE, Bauer LA, Gibson GA, et al. Estimating creatinine clearance in morbidly obese patients. Am J Hosp Pharm 1981; 38:841-4.
60. Christoff PB, Conti DR, Naylor C, et al. Procainamide disposition in obesity. Drug Intell Clin Pharm 1983; 17:516-22.
61. Schwartz SN, Pazin GJ, Lyon JA, et al. A controlled investigation of the pharmacokinetics of gentamycin and tobramycin in obese subjects. J Infect Dis 1978; 138:499-505.
62. Blouin RA, Bauer LA, Miller DD, et al. Vancomycin pharmacokinetics in normal and morbidly obese subjects. Antimicrob Agents Chemother 1982; 21:575-80.
63. Wulfsohn NL. D-Tubocurarine dosage based on lean body mass. Canad Anesth Soc J 1972; 19:251-62.
64. Wulfsohn NL. Succinylcholine dosage based on lean body mass. Canad Anesth Soc J 1972; 19:360-72.
65. Wulfsohn NL. Ketamine dosage for induction based on lean body mass. Anesth Analg 1972; 51:299-305.
66. Wulfsohn NL, Joshi CW. Thiopentone dosage based on lean body mass. Br J Anaesth 1969; 41:516-21.
67. Varin F, Ducharme J, Theoret Y, et al. Influence of extreme obesity on the body disposition and neuromuscular blocking effect of atracurium. Clin Pharmacol Ther 1990; 48:18-25.
68. Schwartz AE, Matteo RS, Ornstein E, et al. Pharmacokinetics and pharmacodynamics of vercuronium in the obese surgical patient. Anesth Analg 1992; 74:515-18.
69. Crankshaw DP, Allt-Graham J. ED50 values for thiopentone, methohexital, propanidid and alfathesin: a clinical experiment. Anesthesia and Intensive Care 1978; 6:36-43.
70. Leslie K, Crankshaw DP. Potency of propofol for loss of consciousness after a single dose. Br J Anesth 1990; 64:734-6.
71. Schwartz AE, Matteo RS, Ornstein E, et al Pharmacokinetics of sufentil in obese patients. Anesthesia and Analgesia 1991; 73:790-3.
72. Bentley JB, Vaughan RW, Gandolfi AJ, et al. Altered halothane metabolism: obese vs nonobese subjects. Anesthesiol 1981; 55:A179.
73. Miller MS, Gandolfi AJ, Vaughan RW, et al. Disposition of enflurane in obese subjects. J Pharmacol Exp Therap 1980; 215:139-42.
74. Forbes GB, Welle SL. Lean body mass in obesity. Int J Obesity 1983; 7:99-107.
75. Cox J, Penn N, Masood M, et al. Drug overdose - a hidden hazard of obesity. J Roy Soc Med 1981; 80:708-9.
76. Bauer LA, Drew Edwards WA, Patchen Dillinger E, et al. Influence of weight on aminoglycosides pharmacokinetics in normal weight and morbidly obese patients. Eur J Clin Pharmacol 1983; 24:143-7.
77. Allard S, Kinzig M, Bolvin G, et al. Intravenous ciprofloxacin disposition in obesity. Clin Pharmacol Ther 1993; 54:368-73.
78. Abemethy DR, Todd EL, Schwartz JB. Caffeine disposition in obesity. Br J Clin Pharmacol 1985; 20:61-6.
79. Caraco Y, Zylber-Katz E, Berry EM, et al. Obesity does not alter caffeine disposition. Clin Pharmacol Ther 1991; 49:177.
80. Charland SL, Plezia PM, Bloom JW, et al. The use of bioelectrical impedence to predict theophylline pharmacokinetics in obese subjects. Clin Pharmacol Ther 1989; 45:131.
81. Bauer LA, Wareing-Tran C, Edwards WAD, et al. Cimetidine clearance in the obese. Clin Pharmacol Ther 1985; 37:425-30.
82. Davis RL, Quenzer RW. Ranitidine pharmacokinetics in morbid obesity. Clin Pharmacol Ther 1990; 47:154.
83. Abernethy DR, Greenblatt DJ, Locniskar A, et al. Obesity effects on nitrazepam distribution. Br J Pharmacol 1986; 22:551-5.
84. Greenblatt DJ, Freidman H, Burnstein ES, et al. Trazodone kinetics: effect of age, gender and obesity. Clin Pharmacol Ther 1987; 42:193-200.
85. Abemethy DR, Schwartz JB. Verapamil pharmacodynamics and disposition in obese hypertensive patients. J Cardiovasc Pharmacol 1988; 11:209-15.
86. Dunn TE, Ludwig EA, Slaughter RI, et al. Pharmacokinetics and pharmacodynamics of methylprednisolone in obesity. Clin Pharmacol Ther 1991; 49:536-49.
87. Flerchner SM, Kolbeinsson ME, Tam J, et al. The impact of body weight on cyclosporine pharmacokinetics in renal transplantation recipients. Transplantation 1989; 47:806-10.
88. Levine RR. Factors affecting the gastrointestinal absorption of drugs. Dig Dis 1970; 15:171-88.